V S Opollo1, X Wu2, M D Hughes2, S Swindells3, A Gupta4, A Hesseling5, G Churchyard6, S Kim7, R Lando1, R Dawson8, V Mave9, A Mendoza10, P Gonzales11, N Kumarasamy12, F von Groote-Bidlingmaier13, F Conradie14, J Shenje15, S N Fontain16, A Garcia-Prats5, A Asmelash17, S Nedsuwan18, L Mohapi19, R Mngqibisa20, A C Garcia Ferreira21, E Okeyo1, L Naini22, L Jones23, B Smith24, N S Shah25. 1. Kenya Medical Research Institute, Kisumu, Kenya. 2. Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 3. University of Nebraska Medical Center, Omaha, Nebraska. 4. Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. 5. Desmond Tutu TB Centre, Stellenbosch University, Tygerberg. 6. The Aurum Institute, Johannesburg, South Africa. 7. Harvard T. H. Chan School of Public Health, Boston, Massachusetts, Frontier Science & Technology Research Foundation, Amherst, New York, USA. 8. University of Cape Town Lung Institute, Mowbray, South Africa. 9. Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit, Pune, India. 10. Asociacion Civil Impacta Salud y Educacion, Barranco Clinical Research Site, Lima. 11. Asociación Civil Impacta Salud y Educación, San Miguel Clinical Research Site (CRS), Lima, Peru. 12. Chennai Antiviral Research and Treatment CRS, Chennai, India. 13. TASK Applied Science CRS, Bellville. 14. University of the Witwatersrand, Helen Joseph Hospital, Johannesburg. 15. South African Tuberculosis Vaccine Initiative, Cape Town, South Africa. 16. GHESKIO (Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunistes) Centers Institute of Infectious Diseases and Reproductive Health, Port-au-Prince, Haiti. 17. Gaborone CRS, Gaborone, Botswana. 18. Prevention and Treatment of HIV infection, Chiangrai Prachanukroh Hospital, Chiangrai, Thailand. 19. Soweto CRS, Johannesburg. 20. Durban International CRS, Durban, South Africa. 21. Instituto Nacional de Infectologia/Fundação Oswaldo Cruz, Brazil. 22. Social & Scientific Systems, Inc, Silver Springs, Maryland. 23. Frontier Science & Technology Research Foundation, Amherst, New York, USA. 24. National Institutes of Health, Bethesda, Maryland. 25. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
SETTING: The household contacts (HHCs) of multidrug-resistant tuberculosis (MDR-TB) index cases are at high risk of tuberculous infection and disease progression, particularly if infected with the human immunodeficiency virus (HIV). HIV testing is important for risk assessment and clinical management. METHODS: This was a cross-sectional, multi-country study of adult MDR-TB index cases and HHCs. All adult and child HHCs were offered HIV testing if never tested or if HIV-negative >1 year previously when last tested. We measured HIV testing uptake and used logistic regression to evaluate predictors. RESULTS: A total of 1007 HHCs of 284 index cases were enrolled in eight countries. HIV status was known at enrolment for 226 (22%) HHCs; 39 (4%) were HIV-positive. HIV testing was offered to 769 (98%) of the 781 remaining HHCs; 544 (71%) agreed to testing. Of 535 who were actually tested, 26 (5%) were HIV-infected. HIV testing uptake varied by site (median 86%, range 0-100%; P < 0.0001), and was lower in children aged <18 years than in adults (59% vs. 78%; adjusted for site P < 0.0001). CONCLUSIONS: HIV testing of HHCs of MDR-TB index cases is feasible and high-yield, with 5% testing positive. Reasons for low test uptake among children and at specific sites-including sites with high HIV prevalence-require further study to ensure all persons at risk for HIV are aware of their status.
SETTING: The household contacts (HHCs) of multidrug-resistant tuberculosis (MDR-TB) index cases are at high risk of tuberculous infection and disease progression, particularly if infected with the human immunodeficiency virus (HIV). HIV testing is important for risk assessment and clinical management. METHODS: This was a cross-sectional, multi-country study of adult MDR-TB index cases and HHCs. All adult and child HHCs were offered HIV testing if never tested or if HIV-negative >1 year previously when last tested. We measured HIV testing uptake and used logistic regression to evaluate predictors. RESULTS: A total of 1007 HHCs of 284 index cases were enrolled in eight countries. HIV status was known at enrolment for 226 (22%) HHCs; 39 (4%) were HIV-positive. HIV testing was offered to 769 (98%) of the 781 remaining HHCs; 544 (71%) agreed to testing. Of 535 who were actually tested, 26 (5%) were HIV-infected. HIV testing uptake varied by site (median 86%, range 0-100%; P < 0.0001), and was lower in children aged <18 years than in adults (59% vs. 78%; adjusted for site P < 0.0001). CONCLUSIONS:HIV testing of HHCs of MDR-TB index cases is feasible and high-yield, with 5% testing positive. Reasons for low test uptake among children and at specific sites-including sites with high HIV prevalence-require further study to ensure all persons at risk for HIV are aware of their status.
Authors: Kartik K Venkatesh; Precious Madiba; Guy De Bruyn; Mark N Lurie; Thomas J Coates; Glenda E Gray Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: N Sarita Shah; Courtney M Yuen; Moonseong Heo; Arielle W Tolman; Mercedes C Becerra Journal: Clin Infect Dis Date: 2013-09-24 Impact factor: 9.079
Authors: Scott E Kellerman; J Stan Lehman; Amy Lansky; Mark R Stevens; Frederick M Hecht; Andrew B Bindman; Pascale M Wortley Journal: J Acquir Immune Defic Syndr Date: 2002-10-01 Impact factor: 3.731
Authors: Alison Wringe; Raphael Isingo; Mark Urassa; Griter Maiseli; Rose Manyalla; John Changalucha; Julius Mngara; Samuel Kalluvya; Basia Zaba Journal: Trop Med Int Health Date: 2008-03 Impact factor: 2.622
Authors: Yodi Mahendradhata; Riris Andono Ahmad; Pierre Lefèvre; Marleen Boelaert; Patrick Van der Stuyft Journal: BMC Public Health Date: 2008-11-12 Impact factor: 3.295
Authors: Khine Wut Yee Kyaw; Nang Thu Thu Kyaw; Myo Su Kyi; Sandar Aye; Anthony D Harries; Ajay M V Kumar; Nay Lynn Oo; Srinath Satyanarayana; Si Thu Aung Journal: PLoS One Date: 2020-06-18 Impact factor: 3.240